List of Excipients in Branded Drug PROCTO-MED HC

Generic Drugs Containing PROCTO-MED HC

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	hydrocortisone	50090-2931	CETYL ALCOHOL
A-S Medication Solutions	hydrocortisone	50090-2931	CITRIC ACID MONOHYDRATE
A-S Medication Solutions	hydrocortisone	50090-2931	GLYCERYL MONOSTEARATE
A-S Medication Solutions	hydrocortisone	50090-2931	ISOPROPYL MYRISTATE
A-S Medication Solutions	hydrocortisone	50090-2931	METHYLPARABEN
A-S Medication Solutions	hydrocortisone	50090-2931	POLYOXYL 40 STEARATE

What are the Most Frequently-Used Excipients in PROCTO-MED HC?

# Of NDCs	Excipient
5	CETYL ALCOHOL
2	CITRIC ACID MONOHYDRATE
2	GLYCERYL MONOSTEARATE
2	ISOPROPYL MYRISTATE
5	METHYLPARABEN
2	POLYOXYL 40 STEARATE

PROCTO-MED HC Excipient Strategy, Formulation Economics, and Commercial Opportunities

Last updated: August 4, 2026

PROCTO-MED HC is a prescription hydrocortisone 2.5% rectal cream. Its commercial value is driven less by active-ingredient exclusivity than by vehicle performance, patient usability, manufacturing efficiency, applicator design, and differentiation in hemorrhoid and anorectal inflammation markets. The listed cream base uses conventional oil-in-water emulsion excipients, including cetyl alcohol, glyceryl monostearate, mineral oil, polysorbate 60, propylene glycol, purified water, stearyl alcohol, and white petrolatum.[1]

The formulation has a low apparent patent barrier. Hydrocortisone is a long-established corticosteroid, and no biologic or biosimilar issue applies. The most credible commercial opportunities are reformulated prescription products, preservative-free or lower-irritancy vehicles, improved rectal delivery systems, combination products, and consumer-oriented extensions that remain within FDA regulatory limits.

What is PROCTO-MED HC and how is it regulated?

PROCTO-MED HC contains hydrocortisone USP at 2.5% in a rectal cream dosage form. Hydrocortisone reduces inflammation and itching associated with anorectal conditions such as hemorrhoids and other inflammatory disorders of the anal and rectal region.

Attribute	Product profile
Product	PROCTO-MED HC
Active ingredient	Hydrocortisone USP
Strength	2.5%
Dosage form	Rectal cream
Route	Rectal and perianal topical administration
Regulatory category	Prescription drug
Therapeutic class	Topical corticosteroid
Primary commercial market	Hemorrhoidal and anorectal inflammatory conditions
Biologic status	Not applicable
Orange Book relevance	Relevant if an approved prescription product has an active listing
Main differentiation lever	Vehicle, delivery system, tolerability, packaging, and access

The 2.5% strength is prescription-oriented. OTC hydrocortisone anorectal products generally use lower strengths and are governed by the FDA monograph framework for anorectal drug products.[2] A commercial product using 2.5% hydrocortisone would generally require prescription positioning unless it qualified under a different FDA pathway.

What excipients are used in PROCTO-MED HC?

The labeled inactive ingredients are consistent with a conventional emollient oil-in-water rectal cream.[1]

Excipient	Likely formulation role	Commercial relevance
Cetyl alcohol	Consistency agent, emollient, co-emulsifier	Supports cream body and skin feel
Glyceryl monostearate	Emulsifier and stabilizer	Helps form and maintain the cream matrix
Mineral oil	Emollient and occlusive vehicle	Supports lubrication and moisture retention
Polysorbate 60	Nonionic emulsifier	Stabilizes oil and water phases
Propylene glycol	Humectant, solvent, and penetration-supporting excipient	Improves water retention and processing; may cause irritation in some patients
Purified water	Continuous aqueous phase	Establishes the cream vehicle
Stearyl alcohol	Thickener, emollient, and co-emulsifier	Controls viscosity and spreadability
White petrolatum	Occlusive emollient	Reduces friction and supports local protection

The formulation strategy is functional rather than novel. It combines fatty alcohols and glyceryl monostearate for structure, mineral oil and petrolatum for occlusion, polysorbate 60 for emulsification, and propylene glycol for humectancy and solvent functionality.

How strong is the PROCTO-MED HC formulation strategy?

The formulation is commercially adequate but offers limited differentiation on ingredient identity alone. Most components are established excipients with broad prior use in topical and rectal products. A competitor would likely be able to design around the formulation without using the same quantitative composition.

The main technical strengths are:

1. A familiar cream texture that supports patient acceptance.
2. Petrolatum and mineral oil, which provide lubrication and occlusion.
3. Fatty alcohols that improve viscosity and physical stability.
4. A nonionic emulsifier system that is generally compatible with corticosteroid creams.
5. A water-containing base that supports spreadability and washability relative to an ointment.

The principal vulnerabilities are formulation tolerability and product experience. Propylene glycol can produce stinging or irritation in sensitive tissue. Fatty alcohols and emulsifiers can also cause contact sensitivity in a subset of users. A water-containing cream requires microbial-control validation and appropriate packaging. The product may also face competition from ointments, suppositories, wipes, foams, and combination hemorrhoid products that offer different sensory or delivery characteristics.

What formulation patents protect PROCTO-MED HC?

No product-specific formulation patent should be assumed from the marketed product name alone. The listed excipients are standard pharmaceutical ingredients, and the active ingredient has been used in topical corticosteroid products for decades.

Potential intellectual-property protection would more likely arise from:

• A narrow quantitative composition.
• A specific emulsion structure or particle-size profile.
• A preservative-free multidose package.
• A rectal applicator or dose-metering system.
• A foam, gel, suppository, or mucoadhesive delivery format.
• A combination with a local anesthetic, vasoconstrictor, protectant, or antimicrobial.
• Manufacturing controls that produce a defined hydrocortisone distribution or release profile.

A composition patent would need meaningful technical distinctions over conventional hydrocortisone creams. Broad claims covering hydrocortisone, petrolatum, mineral oil, fatty alcohols, polysorbates, or propylene glycol would face substantial prior-art and obviousness risk.

When does PROCTO-MED HC lose exclusivity?

PROCTO-MED HC does not appear to have a commercially important modern exclusivity position based on the age of hydrocortisone and the conventional nature of the dosage form. The product’s market position is more likely protected by prescription status, brand recognition, distribution, manufacturing scale, and customer retention than by active patents.

Exclusivity category	Assessment
New chemical entity exclusivity	Not applicable
Biologic exclusivity	Not applicable
Orphan-drug exclusivity	Not indicated
Pediatric exclusivity	No product-specific period identified
Formulation exclusivity	No clear modern exclusivity period identified
Method-of-use exclusivity	No clear product-specific period identified
Patent cliff	Low relevance compared with newer drugs
Generic substitution risk	High if an approved therapeutically equivalent product is available

The exact Orange Book status depends on the relevant FDA listing and the specific applicant record. FDA Orange Book data should be checked by product, strength, dosage form, and applicant because brand ownership and marketing status can change over time.[3]

What is the Orange Book status of PROCTO-MED HC?

The Orange Book is the primary source for approved drug applications, therapeutic-equivalence evaluations, and listed patents for eligible prescription drug products.[3] A product-specific Orange Book conclusion should not be inferred from the trade name, because the same active ingredient may be marketed under multiple names and applications.

For PROCTO-MED HC, the relevant review points are:

• Whether the product has an active FDA approval.
• Whether the application is listed as currently marketed.
• Whether a therapeutically equivalent generic hydrocortisone 2.5% rectal cream exists.
• Whether any patents are listed for the application.
• Whether any regulatory exclusivity remains active.
• Whether the product is approved as a standalone application or under an abbreviated pathway.

If an ANDA is approved as therapeutically equivalent, substitution and pharmacy-level generic competition become the primary commercial risks. If no directly substitutable product is listed, alternative hydrocortisone rectal creams and other anorectal therapies can still compete through prescriber preference and payer coverage.

Which companies are challenging PROCTO-MED HC?

No specific Paragraph IV challenger or active patent litigation should be attributed to PROCTO-MED HC without a current FDA, court, or Orange Book record. Given the apparent age of hydrocortisone and the conventional cream vehicle, Paragraph IV litigation is less likely to be the central competitive issue than ordinary ANDA competition.

What would a Paragraph IV challenge involve?

A generic applicant could challenge any listed patent by certifying that the patent is invalid, unenforceable, or not infringed. The filing could trigger notice to the patent owner and, if litigation follows within the statutory period, a temporary stay of approval under the Hatch-Waxman framework.[4]

For a product with no meaningful listed patents, the generic applicant would generally face a lower litigation burden. The principal barriers would be:

• Demonstrating pharmaceutical equivalence.
• Meeting quality and stability specifications.
• Establishing bioequivalence where required.
• Matching the approved route and dosage form.
• Reproducing the relevant performance of the cream vehicle.

What patent litigation affects the product?

No specific litigation should be treated as affecting PROCTO-MED HC absent a current docket or FDA patent record. Litigation risk would increase if a reformulated product relied on a novel applicator, mucoadhesive system, controlled release profile, or combination therapy.

What commercial opportunities exist for PROCTO-MED HC excipients?

The strongest opportunities involve changing the patient experience without changing the hydrocortisone mechanism.

Preservative-free rectal cream

A preservative-free formulation could target patients with recurrent use, sensitive perianal tissue, or known preservative intolerance. The principal technical challenge is packaging. A single-use tube, unit-dose sachet, or airless pump could reduce contamination risk and support a preservative-free claim.

Commercial benefits include:

• Reduced concern about preservative-related irritation.
• Differentiation from conventional multidose creams.
• Potential use in specialist channels.
• Premium pricing if supported by clinical and sensory data.

The tradeoff is higher packaging cost and more complex supply-chain management.

Lower-irritancy vehicle

A reformulation could evaluate alternatives to propylene glycol, reduce surfactant load, or use a different emulsion system. Candidate strategies include glycerol-based humectancy, lower-irritancy nonionic emulsifiers, or anhydrous ointment systems.

The objective should be measured tolerability, not ingredient novelty. Useful development endpoints include stinging, burning, spreadability, residue, washability, and patient preference.

Mucoadhesive gel

A hydrocortisone gel using a mucoadhesive polymer could increase residence time in the anorectal area. Polymers such as carbomers, cellulose derivatives, or poloxamers may support gel formation, although each introduces risks related to irritation, viscosity, drug release, and manufacturing.

A mucoadhesive product could be positioned around reduced leakage and less frequent application. It would likely require stronger formulation and clinical support than a conventional cream.

Foam delivery

Rectal foam can improve distribution and reduce the greasy feel associated with petrolatum-rich creams. Foam products also allow delivery into the rectal canal with an applicator. The format could support a premium prescription product, but it requires specialized packaging, propellant evaluation, microbial testing, and device compatibility work.

Applicator and dose-control systems

The applicator is an underdeveloped differentiation area. Opportunities include:

• A softer, rounded applicator tip.
• A calibrated dose chamber.
• A disposable single-use applicator.
• A shield designed to reduce contamination.
• Packaging that supports both external and internal application.
• Instructions that reduce dosing errors.

Device claims may provide stronger practical differentiation than claims directed solely to conventional cream ingredients.

How does PROCTO-MED HC compare with competing dosage forms?

Dosage form	Advantages	Limitations	Commercial opportunity
Cream	Spreadable, familiar, washable	May leak or require repeated application	Improve tolerability and packaging
Ointment	Strong occlusion and lubrication	Greasy, difficult to wash	Premium barrier product
Suppository	Internal delivery and retention	Less suitable for external lesions	Combination or extended-residence product
Foam	Broad internal distribution, low residue	Higher packaging complexity	Premium prescription format
Gel	Potential mucoadhesion and lower grease	Irritation and release challenges	Controlled residence-time positioning
Wipe or pad	Convenience and cleansing	Limited drug residence	Adjunctive consumer product

A reformulation should be assessed against patient-use conditions, not only laboratory release. Rectal products must balance retention, comfort, hygiene, ease of application, and short-term symptom relief.

What generic entry risks exist for PROCTO-MED HC?

Generic entry risk is structurally high because hydrocortisone is an old, well-characterized active ingredient and the cream contains conventional excipients. A generic manufacturer could compete through:

• A therapeutically equivalent cream.
• A lower-cost private-label product.
• A pharmacy-channel generic.
• An alternative manufacturer with stronger wholesaler access.
• A product using a similar but nonidentical excipient system.

The brand can reduce substitution pressure through differentiated delivery, documented tolerability, patient-support programs, reliable supply, and payer contracting. Ingredient-level exclusivity is unlikely to provide durable protection.

What manufacturing and IP barriers affect the product?

Manufacturing barriers are moderate rather than high. The formulation uses standard emulsion processing, but quality depends on control of:

• Hydrocortisone dispersion and uniformity.
• Emulsion droplet size.
• Viscosity and spreadability.
• Phase stability.
• Microbial quality.
• Tube and applicator compatibility.
• Extractables and leachables.
• Fill weight and dose delivery.

A scalable process may require controlled heating and cooling of the oil and aqueous phases, validated homogenization, and defined addition order. These process parameters can support trade-secret protection even when the composition is not patentable.

The most defensible IP package for a differentiated product would combine a narrow composition patent, a delivery-device patent, process know-how, stability data, and brand protection. A conventional copy of the existing base would provide a weaker patent position.

What licensing deals could support PROCTO-MED HC growth?

Potential licensing targets include:

• Preservative-free emulsion technology.
• Rectal foam platforms.
• Mucoadhesive polymers.
• Single-use applicator systems.
• Low-irritancy topical delivery vehicles.
• Combination-product technology for hemorrhoidal symptoms.

A licensing deal is most attractive when the technology solves a clear product problem and can be transferred without extensive clinical redevelopment. Platform technologies that require a new clinical endpoint or a new route-of-administration study carry higher development risk.

Key Takeaways

• PROCTO-MED HC is a prescription hydrocortisone 2.5% rectal cream using a conventional emollient emulsion base.
• Its commercial position is unlikely to depend on new-chemical-entity, biologic, or long-term formulation exclusivity.
• The main excipient opportunities are preservative-free packaging, lower-irritancy vehicles, mucoadhesive gels, foams, and improved applicators.
• Generic risk is high because hydrocortisone is established and the listed excipients are widely used.
• A defensible reformulation strategy should combine patient-use data, device differentiation, process know-how, and narrow patent claims.
• Paragraph IV litigation and biosimilar competition are not the primary risk categories for this product.
• FDA Orange Book and current FDA application records determine the product’s exact approval, substitution, patent, and exclusivity status.[3]

FAQs About PROCTO-MED HC Formulation and Commercial Strategy

Is propylene glycol necessary in PROCTO-MED HC?

Propylene glycol can function as a humectant, solvent, and processing aid, but it is not necessarily indispensable. A reformulation could evaluate glycerol or other compatible excipients, subject to stability, release, tolerability, and regulatory testing.

Could PROCTO-MED HC be reformulated as an ointment?

Yes. An anhydrous ointment could increase occlusion and reduce dependence on aqueous-phase microbial control. The tradeoff would be greater greasiness, lower washability, and a potentially different patient-use profile.

Can hydrocortisone 2.5% rectal cream be sold over the counter?

Prescription-to-OTC conversion would require FDA review and would need to address strength, labeling, self-selection, safety, and applicable OTC regulatory requirements. The 2.5% strength should not be assumed to qualify under the standard OTC anorectal pathway.

Is a biosimilar relevant to PROCTO-MED HC?

No. Hydrocortisone is a small-molecule corticosteroid, not a biologic. Competitive products would generally be evaluated as generics or alternative formulations rather than biosimilars.

What is the most valuable excipient innovation for PROCTO-MED HC?

A low-irritancy, preservative-free rectal delivery system with a calibrated single-use applicator offers the clearest commercial differentiation. It addresses tolerability, contamination, dosing, and patient convenience in one product platform.

References

1. DailyMed. (n.d.). PROCTO-MED HC: Hydrocortisone 2.5% rectal cream prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). 21 C.F.R. Part 346: Anorectal drug products for over-the-counter human use. Electronic Code of Federal Regulations.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Refuse-to-receive standards and Paragraph IV certification procedures. FDA.